# INTERNATIONAL TRADE COMMISSION

## **Sunshine Act Meeting**

# Agency Holding the Meeting: International Trade Commission.

TIME AND DATE: February 23, 2004, at 11 a m

**PLACE:** Room 101, 500 E Street, SW., Washington, DC 20436. Telephone: (202) 205–2000.

**STATUS:** Open to the public.

# MATTERS TO BE CONSIDERED:

- 1. Agenda for future meetings: none.
- 2. Minutes.
- 3. Ratification list.
- 4. Inv. No. 731-TA-1069

(Preliminary) (Outboard Engines from Japan)—briefing and vote. (The Commission is currently scheduled to transmit its determination to the Secretary of Commerce on or before February 23, 2004; Commissioners' opinions are currently scheduled to be transmitted to the Secretary of Commerce on or before March 1, 2004.)

5. Outstanding action jackets: none.

In accordance with Commission policy, subject matter listed above, not disposed of at the scheduled meeting, may be carried over to the agenda of the following meeting.

By order of the Commission:

Issued: February 12, 2004.

#### Marilyn R. Abbott,

Secretary to the Commission.

[FR Doc. 04–3549 Filed 2–12–04; 4:50 pm]

BILLING CODE 7020-02-P

## **DEPARTMENT OF JUSTICE**

## **Drug Enforcement Administration**

## Manufacturer of Controlled Substances; Notice of Application

Pursuant to section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on October 23, 2003, Applied Science Labs, Division of Alltech Associates Inc., 2701 Carolean Industrial Drive, P.O. Box 440, State College, Pennsylvania 16801, made application by letter to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic class of controlled substances listed below:

Drug	Schedule
2, 5-dimethoxy-4-(n)- propylthiophenethylaminie (2C-	I
T-7) (7348). Alpha-methyltryptamine (AMT) (7432).	I

Drug		Schedule
5-methoxy-N-, diisopropyltryptamine DIPT) (7439).	N- (5-MeO-	I

The firm plans to manufacture small quantities of the listed controlled substances for reference standards.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Division Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: Federal Register Representative, Office of Chief Counsel (CCD) and must be filed no later than April 19, 2004.

Dated: February 4, 2004.

#### Laura M. Nagel,

Deputy Assistant Administrator, Office of Diversion Control.

[FR Doc. 04–3475 Filed 2–17–04; 8:45 am]
BILLING CODE 4410–09–M

#### **DEPARTMENT OF JUSTICE**

# **Drug Enforcement Administration**

## Manufacturer of Controlled Substances; Notice of Application

Pursuant to section 1301.33(a) of title 21 of the Code of Federal Regulations (CFR), this is notice that on October 29, 2003, Cambrex Charles City, Inc., 1205 11th Street, Charles City, Iowa 50619 made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below.

Drug	Schedule
Amphetamine (1100)  Methylphenidate (1724)  Dextropropoxphene (9273)	       

The firm plans to manufacture bulk controlled substances for distribution to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice,

Washington, DC 20537, Attention: Federal Register Representative, Office of Chief Counsel (CCD) and must be filed no later than April 19, 2004.

Dated: February 4, 2004.

#### Laura M. Nagel,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration

[FR Doc. 04–3481 Filed 2–17–04; 8:45 am] BILLING CODE 4410–09–M

#### **DEPARTMENT OF JUSTICE**

### **Drug Enforcement Administration**

## Manufacturer of Controlled Substances; Notice of Registration

By notices dated March 11, 2003, and published in the **Federal Register** on April 2, 2003 (68 FR 16088), dated April 3, 2003, and published in the Federal Register on April 15, 2003 (68 FR 18262), dated June 20, 2003, and published in the **Federal Register** on July 8, 2003 (68 FR 40686), and dated October 7, 2003, and published in the Federal Register on October 29, 2003 (68 FR 61698), Cody Laboratories, Inc., 331 33rd Street, Cody, Wyoming 82414, made application by letters and by renewals to the Drug Enforcement Administration for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Dihydromorphine (9145)	I.
Amphetamine (1100)	l II
Methamphetamine (1105)	l II
Amobarbital (2125)	II
Pentobarbital (2270)	l II
Secobarbital (2315)	II
Phenylacetone (8501)	II
Oxycodone (9143)	l II
Hydromorphone (9150)	l II
Diphenoxylate (9170)	II
Meperidine (9230)	II
Oxymorphone (9652)	l II
Sufentanil (9740)	l II
Fentanyl (9801)	II

On December 30, 2003, the firm requested that their registration be modified to reflect an address change to 601 Yellowstone Drive, Cody, Wyoming 82414. That modification was effected on January 8, 2004.

The firm plans to manufacture bulk materials for distribution to its customers.

No comments or objections have been received. DEA has considered the factors in title 21, United States Code, section 823(a) and determined that the registration of Cody Laboratories, Inc. to manufacture the listed controlled substances is consistent with the public